funded by @lbg.ac.at
Focusing on disease-driving mechanisms in patients with #PortalHypertension
#LiverFibrosis
T
hank you to all colleagues for your dedication, teamwork, and commitment throughout the year. We’re proud of what we’ve achieved together and look forward to continuing our work in 2026.
Wishing everyone peaceful holidays and a joyful New Year! ✨🎁
T
hank you to all colleagues for your dedication, teamwork, and commitment throughout the year. We’re proud of what we’ve achieved together and look forward to continuing our work in 2026.
Wishing everyone peaceful holidays and a joyful New Year! ✨🎁
We’re growing and evolving as we enter Year 3 — with new roles, fresh perspectives & shared dedication to advance hepatology and improve patient outcomes.
💪 Here’s to another year of teamwork & innovation!
#MOTIONTeam #LiverResearch
We’re growing and evolving as we enter Year 3 — with new roles, fresh perspectives & shared dedication to advance hepatology and improve patient outcomes.
💪 Here’s to another year of teamwork & innovation!
#MOTIONTeam #LiverResearch
His lecture covered liver cirrhosis, CSPH & hepatitis B/D.
💪 We’re proud to have him on our MOTION team!
#Hepatology
His lecture covered liver cirrhosis, CSPH & hepatitis B/D.
💪 We’re proud to have him on our MOTION team!
#Hepatology
Our specialists is working to characterize rebalanced hemostasis in #ACLD & #PSVD using advanced diagnostics like #ClotPro & TM-TGA.
#Portalhypertension #coagulation #liver #Clinicaltrial
Our specialists is working to characterize rebalanced hemostasis in #ACLD & #PSVD using advanced diagnostics like #ClotPro & TM-TGA.
#Portalhypertension #coagulation #liver #Clinicaltrial
UP next is WP5 introduced and led by
@mathiasjachs.bsky.social
🖐️
Developing prognostic #NIT models for #ACLD or #PSVD
📷More info in the video below 📷
UP next is WP5 introduced and led by
@mathiasjachs.bsky.social
🖐️
Developing prognostic #NIT models for #ACLD or #PSVD
📷More info in the video below 📷
Reflected on 2 years of growth & scientific insights, and set course for the next 2 years.
Next step: making our 3 clinical trials – and project MOTION as a whole – an outstanding success! 💫
#MotionProject #TeamScience #ClinicalTrials
Reflected on 2 years of growth & scientific insights, and set course for the next 2 years.
Next step: making our 3 clinical trials – and project MOTION as a whole – an outstanding success! 💫
#MotionProject #TeamScience #ClinicalTrials
Next one is MOTION WP 4 led and introduced by
@mattiasmandorfer.bsky.social
- Comparing #HVPG responses of our medication within our clinical trials to NSBBS...
🌐More info in the video below 📷🔽
Next one is MOTION WP 4 led and introduced by
@mattiasmandorfer.bsky.social
- Comparing #HVPG responses of our medication within our clinical trials to NSBBS...
🌐More info in the video below 📷🔽
Focused on HVPG response to therapy, NIT-based prognostic models, & clinical outcomes in #ACLD/#PSVD.
🔬 A comprehensive approach to #hepatology research.
Led by @mattiasmandorfer.bsky.social & @mathiasjachs.bsky.social
📷More info in the graphic 📷
Focused on HVPG response to therapy, NIT-based prognostic models, & clinical outcomes in #ACLD/#PSVD.
🔬 A comprehensive approach to #hepatology research.
Led by @mattiasmandorfer.bsky.social & @mathiasjachs.bsky.social
📷More info in the graphic 📷
WP lead Dr. Georg Semmler gives a quick introduction into how we’re tackling PSVD—from molecular insights to clinical impact. 💡
Watch now & learn more about our mission in hepatology!
#WP3 #LiverResearch #PSVD #ScienceInMotion
WP lead Dr. Georg Semmler gives a quick introduction into how we’re tackling PSVD—from molecular insights to clinical impact. 💡
Watch now & learn more about our mission in hepatology!
#WP3 #LiverResearch #PSVD #ScienceInMotion
The key element: the EXPOSURE trial, investigating anticoagulation with Edoxaban in PSVD patients.
#MotionProject #PSVD #WP3 #LiverResearch #ClinicalTrials
The key element: the EXPOSURE trial, investigating anticoagulation with Edoxaban in PSVD patients.
#MotionProject #PSVD #WP3 #LiverResearch #ClinicalTrials
In this particular WP the team is focusing on decompensated cirrhosis..
#liver #PortalHypertension #clinicaltrails #dACLD
🔽 Find out more in the video below 📷🔽
In this particular WP the team is focusing on decompensated cirrhosis..
#liver #PortalHypertension #clinicaltrails #dACLD
🔽 Find out more in the video below 📷🔽
A step forward in risk assessment!
📊👇More info 📊👇
lnkd.in/du8-FjgE
A step forward in risk assessment!
📊👇More info 📊👇
lnkd.in/du8-FjgE
#MotionTeam #EASL2025 #LiverResearch #Innovation #ProudToRepresent
#MotionTeam #EASL2025 #LiverResearch #Innovation #ProudToRepresent
🥂🥂 OUR deputy PI
@MattiasMandorf1
.
received the "EASL Emerging Leader Awards 2025" in Amsterdam yesterday at #EALS2025
We congratulate him from the bottom of our #livers 😉 and are incredibly proud!
🙏 to EASL for inspiration, education & support throughout this journey as well as to my mentors & friends! @bavenocoop.bsky.social #LiverSky
🥂🥂 OUR deputy PI
@MattiasMandorf1
.
received the "EASL Emerging Leader Awards 2025" in Amsterdam yesterday at #EALS2025
We congratulate him from the bottom of our #livers 😉 and are incredibly proud!
WP2 focuses on decompensated cirrhosis. Heart of the this wp is a clinical trial led by @reibergerthomas.bsky.social investigating the potential beneficial effects of norfloxacin in this patient group.
⬇️⬇️⬇️⬇️
#liver #liverdesease #PortalHypertension #ClinicalTrial
WP2 focuses on decompensated cirrhosis. Heart of the this wp is a clinical trial led by @reibergerthomas.bsky.social investigating the potential beneficial effects of norfloxacin in this patient group.
⬇️⬇️⬇️⬇️
#liver #liverdesease #PortalHypertension #ClinicalTrial
Introducing MOTION WP 1 - Focusing on pathophysiological mechanisms in compensated Patients with liver cirrhosis....
🌐More info in the video below 🌐 🔽🔽
Introducing MOTION WP 1 - Focusing on pathophysiological mechanisms in compensated Patients with liver cirrhosis....
🌐More info in the video below 🌐 🔽🔽
This WP focuses on the classical & alternative renin-angiotensin system as a disease-driving mechanism in patients with cACLD. The heart of WP1 is a clinical trail to investigate potentially beneficial effects of telmisartan in this patient group.
This WP focuses on the classical & alternative renin-angiotensin system as a disease-driving mechanism in patients with cACLD. The heart of WP1 is a clinical trail to investigate potentially beneficial effects of telmisartan in this patient group.
Just something else.... :) 🌐
When top-notch research meets good energy, magic happens. Work hard, laugh harder — that’s how we roll.
#MOTIONProject #ScienceSquad #FridayFeeling #TeamworkMakesTheDreamWork
Just something else.... :) 🌐
When top-notch research meets good energy, magic happens. Work hard, laugh harder — that’s how we roll.
#MOTIONProject #ScienceSquad #FridayFeeling #TeamworkMakesTheDreamWork
While knowledge is undoubtedly necessary in a project, people form the foundation of success...
Physicians, PhDstudents, PMs, StudyNurses & DataManagers bring their unique skills & perspectives that make our MOTION project truly special
While knowledge is undoubtedly necessary in a project, people form the foundation of success...
Physicians, PhDstudents, PMs, StudyNurses & DataManagers bring their unique skills & perspectives that make our MOTION project truly special
🙌🙌🙌 Congrats and let's celebrate!! 🙌🙌🙌
#liver research @ViennaLiverNews @crgmotion.bsky.social
1⃣ #NSBB improve survival in 2nd🩸prophylaxis
@APandT 🔗 t.ly/tcZ1q
2⃣ #SEMS stent controls severe variceal🩸bleeding
@LiverInt 🔗 t.ly/wcDLo
2⃣ #EVL is safe in ⤵️PLT and ⤴️INR
@HepInt 🔗 t.ly/yKfuT
🙌🙌🙌 Congrats and let's celebrate!! 🙌🙌🙌
A team of clinical & basic researchers, assembled by @reibergerthomas.bsky.social & @mattiasmandorfer.bsky.social to conduct clinical studies & translational research on PH-driving molecular mechanisms.
Those aspiring members are divided in 8 WPs assigned to their expertise.
A team of clinical & basic researchers, assembled by @reibergerthomas.bsky.social & @mattiasmandorfer.bsky.social to conduct clinical studies & translational research on PH-driving molecular mechanisms.
Those aspiring members are divided in 8 WPs assigned to their expertise.
We are thrilled to share that our clinical trial is in full swing!
It is divided in 8 work packages and over the upcoming weeks, we’ll introduce each innovative work package, with the dedicated experts, driving this project forward.
⬇️📷More info 📷⬇️
We are thrilled to share that our clinical trial is in full swing!
It is divided in 8 work packages and over the upcoming weeks, we’ll introduce each innovative work package, with the dedicated experts, driving this project forward.
⬇️📷More info 📷⬇️
⬇️ Follow for more info... ⬇️
#portalhypertension #research #clinicaltrail #liver #blueskyliver
⬇️ Follow for more info... ⬇️
#portalhypertension #research #clinicaltrail #liver #blueskyliver